Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

From today, February 3, pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation ...

Inhalon Biopharma's inhaled RSV antibody treatment will enter human trials marking a potential breakthrough in respiratory ...

Fact checked by Nick Blackmer Despite a temporary freeze on public communications, the Centers for Disease Control and ...

In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...

covering the critical winter RSV season. Uptake of the nirsevimab program so far in Ireland has been high, with 83 percent of eligible infants receiving the treatment. These results have spurred ...

For most people RSV is like a cold, but for infants and older people it can lead to serious infections. Here's what to know.

7. New RSV prevention options for infants and pregnant mothers A new RSV prevention option for infants was introduced in 2023: the monoclonal antibody treatment Beyfortus (nirsevimab). This shot is ...

A new study is showing a policy change in 2016 related to the vaccination of some premature babies for RSV in Nova Scotia led to a tenfold increase in the number of infants in that group that ...